Signaturefd, LLC Eagle Pharmaceuticals, Inc. Transaction History

Signaturefd, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 01, 2023	SELL	$17.74 - $31.87 $20,702 - $37,192	-1,167 Reduced 74.76%	394 $7,000
Q1 2023 Apr 28, 2023	BUY	$25.06 - $34.09 $25,962 - $35,317	1,036 Added 197.33%	1,561 $44,000
Q4 2022 Jan 27, 2023	BUY	$24.98 - $39.77 $1,473 - $2,346	59 Added 12.66%	525 $15,000
Q3 2022 Nov 08, 2022	SELL	$26.42 - $47.12 $5,944 - $10,602	-225 Reduced 32.56%	466 $12,000
Q2 2022 Aug 10, 2022	BUY	$41.26 - $51.35 $22,445 - $27,934	544 Added 370.07%	691 $31,000
Q1 2022 May 02, 2022	BUY	$44.58 - $52.6 $2,630 - $3,103	59 Added 67.05%	147 $7,000
Q4 2021 Jan 25, 2022	SELL	$45.82 - $56.9 $1,603 - $1,991	-35 Reduced 28.46%	88 $4,000
Q3 2021 Oct 28, 2021	BUY	$43.79 - $55.78 $525 - $669	12 Added 10.81%	123 $7,000
Q2 2021 Jul 26, 2021	BUY	$36.86 - $44.5 $700 - $845	19 Added 20.65%	111 $5,000
Q1 2021 Apr 30, 2021	SELL	$40.32 - $50.97 $120 - $152	-3 Reduced 3.16%	92 $4,000
Q3 2020 Nov 03, 2020	BUY	$37.02 - $51.28 $2,739 - $3,794	74 Added 352.38%	95 $4,000
Q2 2020 Jul 30, 2020	BUY	$43.24 - $55.02 $908 - $1,155	21 New	21 $1,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

Stay updated on Signaturefd, LLC with notifications on news.